

1 March 2021

## Intuitive Investments Group plc

### Investment in Shield Therapeutics plc

Intuitive Investments Group plc (AIM: IIG) (“**IIG**” or the “**Company**”), a closed-end investment company focussed on the life sciences sector, announces an investment of £250,000 to acquire 833,333 ordinary shares of Shield Therapeutics plc (AIM: STX) (“**Shield**”) at a price of 30 pence per share (the “**Investment**”). The Investment is part of Shield’s fundraising as announced by Shield on 26 February 2021 (the “**Fundraising**”). The Investment is conditional upon, amongst other things, each of the resolutions being passed at Shield’s forthcoming general meeting.

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru<sup>®</sup> /Accrufer<sup>®</sup> (ferric maltol)<sup>®</sup>, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Robert Naylor has personally invested £68,600 as part of the Fundraising. Accordingly, Robert Naylor did not vote as a member of the Investment Team of IIG approving the Investment.

The Investment in is the Company's seventh investment following its IPO in mid-December 2020.

#### For further information, please contact:

##### Intuitive Investments Group plc

David Evans, Executive Chairman  
Robert Naylor, CEO

[www.iigplc.com](http://www.iigplc.com)

Via Walbrook PR

##### Strand Hanson Limited - Nominated Adviser

James Harris / James Dance / James Bellman

+44 (0) 20 7409 3494

+44 (0) 20 3657 0050

##### Turner Pope Investments (TPI) Ltd - Broker

Andrew Thacker / Zoe Alexander

##### Walbrook PR Limited - Media & Investor Relations

Paul McManus

+44 (0)20 7933 8780

or [intuitive@walbrookpr.com](mailto:intuitive@walbrookpr.com)

+44 (0) 7980 541 893

#### About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.